| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H14O3 |
| Molecular Weight | 242.2699 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C(C=C1)[C@H]2COC3=CC(O)=CC=C3C2
InChI
InChIKey=ADFCQWZHKCXPAJ-GFCCVEGCSA-N
InChI=1S/C15H14O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8,12,16-17H,7,9H2/t12-/m1/s1
| Molecular Formula | C15H14O3 |
| Molecular Weight | 242.2699 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
EQUOL, (-)- is the (S)-enantiomer of the naturally-occurring isoflavandiol estrogen, equol. EQUOL, (-)- (US-131), is a first-in-class, nonsteroidal, nonhormonal, small molecule (S-equol) that has higher selectivity toward estrogen receptor β (ERβ) than to estrogen receptor α (ERα). S-equol is the exclusive product of human intestinal bacterial synthesis from soy isoflavones. Two-Phase 1 studies have seen completed and published; AUS-131 was safe and well-tolerated in humans. A Phase 2a trial in menopausal women with vasomotor symptoms (VMS) has recently been completed (169 patients). A second Phase 2a trial in men with benign prostatic hyperplasia (BPH) is on track.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
The following doses have been studied in scientific research:
BY MOUTH:
For menopausal symptoms such as hot flashes: 10-40 mg per day in divided doses.
For preventing weak bones (osteoporosis): 10 mg per day.
For reducing skin wrinkles: 5 or 15 mg two times per day.
For metabolic syndrome: 10 mg per day.
Route of Administration:
Oral
